Crescendo Biologics Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Crescendo Biologics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014062
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Crescendo Biologics Ltd (Crescendo) is a biopharmaceutical company that manufactures antibody therapeutics based on a transgenic mouse platform. The company s pipeline includes humabody programs targeting oncology. It specializes in the antibody discoveries and development that include CAT, medimmune, morphosys and GSK. Crescendo develops a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The company’s oncology programmes produce high value, novel therapeutics that capitalizes on advantages of the Humabody VH format. Crescendo is headquartered in Cambridge, the UK.

Crescendo Biologics Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Crescendo Biologics Raises Funds through Venture Financing 10
Crescendo Biologics Raises US$3.3 Million In Series A Financing 11
Crescendo Biologics Raises US$28 Million In Series A Financing 12
Licensing Agreements 14
Takeda Pharma Enters into Licensing Agreement with Crescendo Biologics 14
Crescendo Biologics Ltd – Key Competitors 15
Crescendo Biologics Ltd – Key Employees 16
Crescendo Biologics Ltd – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Corporate Communications 18
Jun 14, 2017: Crescendo Biologics Appoints Edward J. Stewart as Chief Business Officer 18
Apr 03, 2017: Crescendo Biologics Appoints Philip Bland-Ward as Chief Scientific Officer 19
Oct 18, 2016: Crescendo Biologics Appoints Theodora Harold as Chief Financial Officer 20
Product News 21
02/08/2016: Crescendo Biologics Presents Key Oncology Data on Humabody Drug Conjugates 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Crescendo Biologics Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Crescendo Biologics Raises Funds through Venture Financing 10
Crescendo Biologics Raises US$3.3 Million In Series A Financing 11
Crescendo Biologics Raises US$28 Million In Series A Financing 12
Takeda Pharma Enters into Licensing Agreement with Crescendo Biologics 14
Crescendo Biologics Ltd, Key Competitors 15
Crescendo Biologics Ltd, Key Employees 16

★海外企業調査レポート[Crescendo Biologics Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fractyl Laboratories Inc:医療機器:M&Aディール及び事業提携情報
    Summary Fractyl Laboratories Inc (Fractyl) is a clinical-stage medical technology company that develops novel devices and procedures to overcome insulin resistance and restitute metabolic health. The company developed a device-based clinical platform to change the way of treating metabolic diseases. …
  • Australian Broadcasting Corporation:企業の戦略的SWOT分析
    Australian Broadcasting Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Yanzhou Coal Mining Co Ltd:戦略・SWOT・企業財務分析
    Yanzhou Coal Mining Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Yanzhou Coal Mining Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Internet Initiative Japan Inc (3774):企業の財務・戦略的SWOT分析
    Internet Initiative Japan Inc (3774) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Smrt Corporation Ltd.
    Smrt Corporation Ltd. - Strategy, SWOT and Corporate Finance Report Summary Smrt Corporation Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • MannKind Corp (MNKD):企業の財務・戦略的SWOT分析
    MannKind Corp (MNKD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • AEON Credit Service (Asia) Co., Ltd.:企業の戦略・SWOT・財務情報
    AEON Credit Service (Asia) Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary AEON Credit Service (Asia) Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Cerus Corp (CERS):医療機器:M&Aディール及び事業提携情報
    Summary Cerus Corp (Cerus) is a biomedical products company that focuses in the field of blood transfusion safety. It develops and commercializes the INTERCEPT Blood System to enhance blood safety. INTERCEPT Blood System reduces the risk of transfusion-transmitted infections by inactivating a wide r …
  • Intracom Holdings SA (INTRK):企業の財務・戦略的SWOT分析
    Intracom Holdings SA (INTRK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Fomento de Construcciones y Contratas S.A.:企業の戦略・SWOT・財務分析
    Fomento de Construcciones y Contratas S.A. - Strategy, SWOT and Corporate Finance Report Summary Fomento de Construcciones y Contratas S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Sanofi (SAN):企業の財務・戦略的SWOT分析
    Sanofi (SAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Turbo Power Systems Ltd:企業の戦略的SWOT分析
    Turbo Power Systems Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Blade Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Blade Therapeutics Inc (Blade Therapeutics) is a biopharmaceutical company which develops novel anti-fibrotic therapies to treat various fibrotic disorders. Its lead program is a small molecule inhibitor targeting an intracellular cysteine protease associated with fibrosis across diverse ind …
  • Syncardia Systems LLC:企業の戦略的SWOT分析
    Syncardia Systems LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Fusion Telecommunications International, Inc.:企業のM&A・事業提携・投資動向
    Fusion Telecommunications International, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Fusion Telecommunications International, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, …
  • Breville Group Ltd (BRG):企業の財務・戦略的SWOT分析
    Breville Group Ltd (BRG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Tepha Inc:企業の製品パイプライン分析
    Summary Tepha Inc (Tepha) is a medical device firm that develops and commercializes biomaterial technology products. The firm offers products such as absorbable monofilament suture, absorbable monofilament mesh, composite mesh and absorbable surgical film. It also provides platforms including absorb …
  • Miromatrix Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Miromatrix Medical Inc (Miromatrix Medical) is a biotechnology company engaged in the development extracellular matrix based medical devices in soft tissue reinforcement and advanced wound care. The company offers MIRODERM a porcine liver-derived noncrosslinked acellular biologic wound matri …
  • Alcon Laboratories Inc:製品パイプライン分析
    Summary Alcon Laboratories Inc (Alcon), a division of Novartis AG, develops and manufactures devices in the field of Ophthalmology. The company’s portfolio encompasses contact lenses and surgical products. Alcon’s products are used for the treatment of various conditions such as cataracts, glaucoma, …
  • Krka, d. d., Novo mesto:企業の戦略・SWOT・財務情報
    Krka, d. d., Novo mesto - Strategy, SWOT and Corporate Finance Report Summary Krka, d. d., Novo mesto - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆